<p>Omnicell ((OMCL)) 已召开其第一季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>Omnicell 最近的财报电话会议语气明显乐观，管理层强调了强劲的收入增长、显著提高的盈利能力和健康的现金生成。高管们承认了宏观和时机风险，但强调了稳固的产品管道、客户对新平台的强烈兴趣，以及足够的财务灵活性来支持投资，同时提高了全年盈利指引。</p>
<h2>顶线收入增长</h2>
<p>Omnicell 在本季度开局良好，报告第一季度收入为 3.1 亿美元，同比增长 15%，并在之前预期的上限结束。管理层将这一表现视为公司药物管理和自动化解决方案需求依然强劲的证据，尽管医疗客户的情况参差不齐。</p>
<h2>产品和服务收入强劲</h2>
<p>产品销售引领增长，收入为 1.75 亿美元，比去年增长 20%，反映出硬件需求强劲以及新产品的早期贡献。服务收入达到 1.35 亿美元，同比增长 8%，而经常性收入持续扩大，得益于专业和消耗品，管理层认为这对平滑周期性波动至关重要。</p>
<h2>盈利能力显著改善</h2>
<p>盈利能力出现显著好转，非 GAAP EBITDA 从一年前的 2400 万美元攀升至 4500 万美元，非 GAAP 每股收益翻倍至 0.55 美元。在 GAAP 基础上，Omnicell 的每股收益为 0.25 美元，而去年同期为亏损 0.15 美元，突显了成本措施和更好的运营杠杆对收入增长的影响。</p>
<h2>毛利和自由现金流指标改善</h2>
<p>毛利率和现金流也朝着正确的方向发展，非 GAAP 毛利率达到约 46%，高于去年第一季度的 42%，并超出 2025 年的全年水平。自由现金流激增至 3900 万美元，而去年仅为 1000 万美元，为公司提供了更多资金以支持增长计划并吸收短期成本压力。</p>
<h2>指导和财务目标加强</h2>
<p>公司维持全年收入和订单预期，但提高了盈利目标，显示出对执行的信心。管理层将产品订单指引保持在 5.1 亿至 5.6 亿美元之间，年末年经常性收入（ARR）目标为 6.8 亿至 7 亿美元，同时提高了非 GAAP EBITDA 和每股收益的范围，以反映更强的毛利率。</p>
<h2>战略产品发布和早期反响</h2>
<p>Omnicell 突出了其新款 Titan XT 系统和 OmniSphere 平台作为战略增长驱动因素，提到第一季度已收到初步的 Titan XT 订单。硬件发货计划在 2026 年下半年进行，OmniSphere 将在 2027 年上半年分阶段推出，早期客户反馈强调了工作流程效率和库存优势。</p>
<h2>商业势头和竞争机会</h2>
<p>除了新产品外，公司还指出了强大的产品管道和增加的竞争胜利，包括与美国退伍军人事务部和一家主要学术医疗中心的扩展部署。对演示和更广泛商业参与的需求有所增加，表明 Omnicell 在医疗系统重新评估自动化供应商时正在获得市场份额。</p>
<h2>资产负债表行动和资本配置</h2>
<p>管理层强调了更为严谨的资本配置立场，提到偿还了 1.75 亿美元的债务，该债务原定于 2025 年到期，并提前回购了约 7800 万美元的股票。这些举措在削减杠杆的同时，传达了对业务的信心，尽管与去年相比减少了现金缓冲。</p>
<h2>现金余额低于去年</h2>
<p>现金及现金等价物在本季度结束时为 2.39 亿美元，低于去年同期的 3.87 亿美元，主要是由于偿还债务和股票回购。尽管这一较低的余额在短期内略微收紧了流动性，但管理层认为改善的现金生成和减少的义务抵消了一些感知风险。</p>
<h2>Titan XT 短期收入节奏</h2>
<p>投资者被提醒，Titan XT 的财务影响将逐步建立，由于医疗系统的资本审批流程漫长，预计 2026 年仅会有适度的增量收入。该产品的订单预计将在下半年集中，这意味着其全面的收益贡献可能在未来几年更为明显。</p>
<h2>关税相关成本压力</h2>
<p>Omnicell 在其 2026 年展望中纳入了估计的 1200 万美元的关税相关成本，承认这些外部压力将对损益表产生影响。管理层强调关税政策仍然不稳定，暗示未来的监管发展可能带来潜在的上行或下行风险。</p>
<h2>潜在的利润和收入波动</h2>
<p>高管们警告称，由于产品和服务组合、发货时机以及分阶段的运营费用驱动了一些波动，季度业绩可能会出现波动。一些支出故意被推迟到第二和第三季度，这可能会暂时对毛利率施加压力，即使全年盈利能力持续上升。</p>
<h2>零售部门的压力</h2>
<p>公司的零售药房暴露，特别是通过 EnlivenHealth，仍然是一个软肋，因为该部门继续面临波动和不确定的环境。尽管最近的行业会议评论暗示情况略有好转，但管理层明确表示零售仍然承压，可能会限制上行空间，直到情况稳定。</p>
<h2>资本审批周期风险</h2>
<p>除了关税和零售疲软，Omnicell 还指出，较长的资本审批周期和相对年轻的 XT 安装基础是 Titan XT 更换进度的风险。这些因素可能会延迟更广泛的采用并推迟订单，进一步强调了经常性收入和服务在缓冲时间波动中的重要性。</p>
<h2>前瞻性指引和展望</h2>
<p>对于第二季度，Omnicell 指导收入在 3.07 亿至 3.13 亿美元之间，非 GAAP EBITDA 在 3700 万至 4200 万美元之间，每股收益在 0.40 至 0.48 美元之间，展望与其增长和利润率轨迹一致。预计到 2026 年，总收入将在 12.15 亿至 12.55 亿美元之间，尽管吸收了假设的 15% 税率和 1200 万美元的关税拖累，但非 GAAP EBITDA 和每股收益范围仍将更高。</p>
<p>Omnicell 的财报电话会议描绘了一幅公司坚定回归进攻的图景，在投资下一代平台与更严格的成本控制和更强的现金纪律之间取得平衡。尽管较长的销售周期、关税和零售逆风带来了不确定性，但双位数的增长、上升的利润率和提高的指引使投资者对未来一年持谨慎乐观的态度。</p>

OMCL

<p>Omnicell 的第一季度财报电话会议强调了强劲的收入增长，同比增加 15%，达到 3.1 亿美元，并且显著改善了盈利能力，非 GAAP EBITDA 上升至 4500 万美元。公司提高了全年利润指引，同时维持了收入目标。包括 Titan XT 系统在内的新产品发布预计将推动未来增长。然而，管理层承认由于产品组合和时机的原因，可能会出现与关税相关的成本和季度业绩的波动</p>

<p>Omnicell ((OMCL)) has held its Q1 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Omnicell ((OMCL)) 已召开其第一季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Omnicell’s latest earnings call struck a notably upbeat tone as management highlighted robust revenue growth, sharply higher profitability, and healthier cash generation. Executives acknowledged macro and timing risks, but emphasized a solid pipeline, strong customer interest in new platforms, and enough financial flexibility to support investment while lifting full‑year profit guidance.</p>
<div class="lb-trans"><p>Omnicell 最近的财报电话会议语气明显乐观，管理层强调了强劲的收入增长、显著提高的盈利能力和健康的现金生成。高管们承认了宏观和时机风险，但强调了稳固的产品管道、客户对新平台的强烈兴趣，以及足够的财务灵活性来支持投资，同时提高了全年盈利指引。</p>
</div><h2>Top-Line Revenue Growth</h2>
<div class="lb-trans"><h2>顶线收入增长</h2>
</div><p>Omnicell opened the quarter with clear momentum, reporting Q1 revenue of $310 million, up 15% year over year and finishing at the upper end of its prior outlook. Management framed this performance as evidence that demand for the company’s medication management and automation solutions remains resilient despite mixed conditions across healthcare customers.</p>
<div class="lb-trans"><p>Omnicell 在本季度开局良好，报告第一季度收入为 3.1 亿美元，同比增长 15%，并在之前预期的上限结束。管理层将这一表现视为公司药物管理和自动化解决方案需求依然强劲的证据，尽管医疗客户的情况参差不齐。</p>
</div><h2>Product and Service Revenue Strength</h2>
<div class="lb-trans"><h2>产品和服务收入强劲</h2>
</div><p>Product sales led the way with revenue of $175 million, a 20% jump versus the prior year, reflecting solid hardware demand and early contributions from newer offerings. Services revenue reached $135 million, up 8% year over year, and recurring revenue continued to expand, helped by Specialty and Consumables, which management sees as key to smoothing cyclicality.</p>
<div class="lb-trans"><p>产品销售引领增长，收入为 1.75 亿美元，比去年增长 20%，反映出硬件需求强劲以及新产品的早期贡献。服务收入达到 1.35 亿美元，同比增长 8%，而经常性收入持续扩大，得益于专业和消耗品，管理层认为这对平滑周期性波动至关重要。</p>
</div><h2>Material Profitability Improvement</h2>
<div class="lb-trans"><h2>盈利能力显著改善</h2>
</div><p>Profitability showed a sharp turnaround, with non‑GAAP EBITDA climbing to $45 million from $24 million a year earlier and non‑GAAP EPS more than doubling to $0.55. On a GAAP basis, Omnicell posted EPS of $0.25 versus a loss of $0.15 in the prior year, underscoring the impact of cost actions and better operating leverage as revenue scales.</p>
<div class="lb-trans"><p>盈利能力出现显著好转，非 GAAP EBITDA 从一年前的 2400 万美元攀升至 4500 万美元，非 GAAP 每股收益翻倍至 0.55 美元。在 GAAP 基础上，Omnicell 的每股收益为 0.25 美元，而去年同期为亏损 0.15 美元，突显了成本措施和更好的运营杠杆对收入增长的影响。</p>
</div><h2>Improving Gross and Free Cash Metrics</h2>
<div class="lb-trans"><h2>毛利和自由现金流指标改善</h2>
</div><p>Margins and cash flow also moved in the right direction, as non‑GAAP gross margin reached about 46%, up from 42% in last year’s first quarter and ahead of the full‑year 2025 level. Free cash flow surged to $39 million compared with just $10 million a year ago, giving the company more room to fund growth initiatives and absorb near‑term cost headwinds.</p>
<div class="lb-trans"><p>毛利率和现金流也朝着正确的方向发展，非 GAAP 毛利率达到约 46%，高于去年第一季度的 42%，并超出 2025 年的全年水平。自由现金流激增至 3900 万美元，而去年仅为 1000 万美元，为公司提供了更多资金以支持增长计划并吸收短期成本压力。</p>
</div><h2>Strengthened Guidance and Financial Targets</h2>
<div class="lb-trans"><h2>指导和财务目标加强</h2>
</div><p>The company maintained its full‑year revenue and bookings outlook but raised profitability targets, signaling confidence in execution. Management kept product bookings guidance at $510 million to $560 million and year‑end ARR at $680 million to $700 million, while lifting non‑GAAP EBITDA and EPS ranges to reflect stronger margins.</p>
<div class="lb-trans"><p>公司维持全年收入和订单预期，但提高了盈利目标，显示出对执行的信心。管理层将产品订单指引保持在 5.1 亿至 5.6 亿美元之间，年末年经常性收入（ARR）目标为 6.8 亿至 7 亿美元，同时提高了非 GAAP EBITDA 和每股收益的范围，以反映更强的毛利率。</p>
</div><h2>Strategic Product Launch and Early Traction</h2>
<div class="lb-trans"><h2>战略产品发布和早期反响</h2>
</div><p>Omnicell spotlighted its new Titan XT system and OmniSphere platform as strategic growth drivers, citing initial Titan XT orders booked in the first quarter. Hardware shipments are slated for the second half of 2026 and OmniSphere’s phased rollout in the first half of 2027, with early customer feedback highlighting workflow efficiencies and inventory benefits.</p>
<div class="lb-trans"><p>Omnicell 突出了其新款 Titan XT 系统和 OmniSphere 平台作为战略增长驱动因素，提到第一季度已收到初步的 Titan XT 订单。硬件发货计划在 2026 年下半年进行，OmniSphere 将在 2027 年上半年分阶段推出，早期客户反馈强调了工作流程效率和库存优势。</p>
</div><h2>Commercial Momentum and Competitive Opportunity</h2>
<div class="lb-trans"><h2>商业势头和竞争机会</h2>
</div><p>Beyond new products, the company pointed to a robust pipeline and increased competitive wins, including expanded deployments with the U.S. Department of Veterans Affairs and a major academic medical center. Demand for demonstrations and broader commercial engagement has picked up, suggesting Omnicell is gaining share as health systems reassess automation vendors.</p>
<div class="lb-trans"><p>除了新产品外，公司还指出了强大的产品管道和增加的竞争胜利，包括与美国退伍军人事务部和一家主要学术医疗中心的扩展部署。对演示和更广泛商业参与的需求有所增加，表明 Omnicell 在医疗系统重新评估自动化供应商时正在获得市场份额。</p>
</div><h2>Balance Sheet Actions and Capital Allocation</h2>
<div class="lb-trans"><h2>资产负债表行动和资本配置</h2>
</div><p>Management underscored a more disciplined capital allocation stance, noting the repayment of $175 million of debt that was due in 2025 and earlier repurchases of roughly $78 million of stock. These moves trimmed leverage while signaling confidence in the business, even as they reduced the cash cushion compared with last year.</p>
<div class="lb-trans"><p>管理层强调了更为严谨的资本配置立场，提到偿还了 1.75 亿美元的债务，该债务原定于 2025 年到期，并提前回购了约 7800 万美元的股票。这些举措在削减杠杆的同时，传达了对业务的信心，尽管与去年相比减少了现金缓冲。</p>
</div><h2>Lower Cash Balance Versus Prior Year</h2>
<div class="lb-trans"><h2>现金余额低于去年</h2>
</div><p>Cash and equivalents ended the quarter at $239 million, down from $387 million a year earlier, largely because of the debt paydown and buybacks. While this lower balance modestly tightens near‑term liquidity, management argued that improved cash generation and reduced obligations offset some of the perceived risk.</p>
<div class="lb-trans"><p>现金及现金等价物在本季度结束时为 2.39 亿美元，低于去年同期的 3.87 亿美元，主要是由于偿还债务和股票回购。尽管这一较低的余额在短期内略微收紧了流动性，但管理层认为改善的现金生成和减少的义务抵消了一些感知风险。</p>
</div><h2>Titan XT Near-Term Revenue Pacing</h2>
<div class="lb-trans"><h2>Titan XT 短期收入节奏</h2>
</div><p>Investors were reminded that Titan XT’s financial impact will build gradually, with only modest incremental revenue expected in 2026 due to lengthy capital approval processes at health systems. Bookings for the product are expected to be back‑half weighted, meaning the full earnings contribution will likely be more visible in subsequent years.</p>
<div class="lb-trans"><p>投资者被提醒，Titan XT 的财务影响将逐步建立，由于医疗系统的资本审批流程漫长，预计 2026 年仅会有适度的增量收入。该产品的订单预计将在下半年集中，这意味着其全面的收益贡献可能在未来几年更为明显。</p>
</div><h2>Tariff-Related Cost Headwind</h2>
<div class="lb-trans"><h2>关税相关成本压力</h2>
</div><p>Omnicell incorporated an estimated $12 million of tariff‑related costs into its 2026 outlook, acknowledging that these external pressures will weigh on the profit and loss statement. Management emphasized that tariff policies remain fluid, suggesting potential upside or downside depending on future regulatory developments.</p>
<div class="lb-trans"><p>Omnicell 在其 2026 年展望中纳入了估计的 1200 万美元的关税相关成本，承认这些外部压力将对损益表产生影响。管理层强调关税政策仍然不稳定，暗示未来的监管发展可能带来潜在的上行或下行风险。</p>
</div><h2>Potential Margin and Revenue Volatility</h2>
<div class="lb-trans"><h2>潜在的利润和收入波动</h2>
</div><p>Executives cautioned that quarterly results may be choppy as product and service mix, shipment timing, and phased operating expenses drive some volatility. Some spending has been deliberately shifted into the second and third quarters, which could temporarily pressure margins even if full‑year profitability continues to trend higher.</p>
<div class="lb-trans"><p>高管们警告称，由于产品和服务组合、发货时机以及分阶段的运营费用驱动了一些波动，季度业绩可能会出现波动。一些支出故意被推迟到第二和第三季度，这可能会暂时对毛利率施加压力，即使全年盈利能力持续上升。</p>
</div><h2>Retail Segment Headwinds</h2>
<div class="lb-trans"><h2>零售部门的压力</h2>
</div><p>The company’s retail pharmacy exposure, particularly through EnlivenHealth, remains a soft spot, as this segment continues to face a choppy and uncertain environment. While recent industry conference commentary suggested a slightly better tone, management was clear that retail remains under pressure and could limit upside until conditions stabilize.</p>
<div class="lb-trans"><p>公司的零售药房暴露，特别是通过 EnlivenHealth，仍然是一个软肋，因为该部门继续面临波动和不确定的环境。尽管最近的行业会议评论暗示情况略有好转，但管理层明确表示零售仍然承压，可能会限制上行空间，直到情况稳定。</p>
</div><h2>Capital Approval Cycle Risks</h2>
<div class="lb-trans"><h2>资本审批周期风险</h2>
</div><p>In addition to tariffs and retail weakness, Omnicell flagged long capital approval cycles and a relatively young installed XT base as risks to the pacing of Titan XT replacements. These factors could delay broader adoption and push out bookings, reinforcing the importance of recurring revenue and services to buffer timing swings.</p>
<div class="lb-trans"><p>除了关税和零售疲软，Omnicell 还指出，较长的资本审批周期和相对年轻的 XT 安装基础是 Titan XT 更换进度的风险。这些因素可能会延迟更广泛的采用并推迟订单，进一步强调了经常性收入和服务在缓冲时间波动中的重要性。</p>
</div><h2>Forward-Looking Guidance and Outlook</h2>
<div class="lb-trans"><h2>前瞻性指引和展望</h2>
</div><p>For the second quarter, Omnicell guided revenue to $307 million to $313 million with non‑GAAP EBITDA of $37 million to $42 million and EPS of $0.40 to $0.48, framing the outlook as consistent with its growth and margin trajectory. For 2026, total revenue is expected between $1.215 billion and $1.255 billion, with higher non‑GAAP EBITDA and EPS ranges despite absorbing an assumed 15% tax rate and the $12 million tariff drag.</p>
<div class="lb-trans"><p>对于第二季度，Omnicell 指导收入在 3.07 亿至 3.13 亿美元之间，非 GAAP EBITDA 在 3700 万至 4200 万美元之间，每股收益在 0.40 至 0.48 美元之间，展望与其增长和利润率轨迹一致。预计到 2026 年，总收入将在 12.15 亿至 12.55 亿美元之间，尽管吸收了假设的 15% 税率和 1200 万美元的关税拖累，但非 GAAP EBITDA 和每股收益范围仍将更高。</p>
</div><p>Omnicell’s earnings call painted the picture of a company firmly back on offense, balancing investment in next‑generation platforms with tighter cost control and stronger cash discipline. While long sales cycles, tariffs, and retail headwinds introduce uncertainty, the combination of double‑digit growth, rising margins, and raised guidance leaves investors with a cautiously optimistic narrative for the year ahead.</p>
<div class="lb-trans"><p>Omnicell 的财报电话会议描绘了一幅公司坚定回归进攻的图景，在投资下一代平台与更严格的成本控制和更强的现金纪律之间取得平衡。尽管较长的销售周期、关税和零售逆风带来了不确定性，但双位数的增长、上升的利润率和提高的指引使投资者对未来一年持谨慎乐观的态度。</p>
</div>

Omnicell 财报电话会议重点突出利润和发展势头